Dong-A ST

Focus: Dong-A ST is a South Korean pharmaceutical company with a diversified portfolio spanning drugs, devices, and diagnostics across metabolic, cardiovascular, oncology, neurology, and gastroenterology indications. The company operates as a mid-cap regional player with a strong clinical development footprint.

Metabolic Diseases Cardiovascular Oncology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dong-A ST

AI assessmentNot Hiring

No open roles listed right now. Follow Dong-A ST to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Fisrt period TWLO_C

Healthy

N/A

Clinical Trials (1)

NCT03932435Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab"

N/A

Help build intelligence for Dong-A ST

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Broad therapeutic portfolio across 5+ disease areas provides diverse career development opportunities in oncology, endocrinology, and gastroenterology
Active clinical pipeline with 30 programs at various stages suggests ongoing investment in R&D and drug development roles
Regional headquarters position in Seoul offers exposure to Asian pharmaceutical market dynamics and regulatory pathways

Watch Out For

Pipeline heavily skewed toward Phase 1 (14 of 20 trials) indicates limited near-term commercial catalysts and regulatory approvals
No publicly disclosed financial data, hiring numbers, or revenue figures limits transparency for evaluating company stability and growth trajectory
Zero active job openings at time of analysis suggests limited immediate hiring and potential organizational constraints

Generated by Claude from Dong-A ST's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Observation only

Liver Fibroses

N/A

Clinical Trials (1)

NCT03042520Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment

N/A

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Growth Hormone Deficiency

N/A

Clinical Trials (1)

NCT04798690Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

N/A

Fractional flow reserve, Coronary CT angiography

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT04547231Impact of Coronary CT Angiography, Physiologic Assessment and Pharmacotherapy on the Clinical Outcomes

N/A

Dual-combination therapy

Type 2 Diabetes

N/A

Evogliptin

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT04326166Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

N/A

No intervention

COVID-19

N/A

Clinical Trials (1)

NCT04834752Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

N/A

Resting full-cycle ratio

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT06075160Resting Full-cycle Ratio (RFR)-Guided Revascularization

N/A

Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

Chronic Hepatitis B

N/A

Clinical Trials (1)

NCT04646928Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

N/A

IGAD→GSTD

Gastroduodenal Ulcer

N/A

Clinical Trials (1)

NCT04123899BE Study of Gaster®D Tab 20mg (Manufacturer Changed)

N/A

WATCH-PAT

Obstructive Sleep Apnea

N/A

Clinical Trials (1)

NCT03600246Prospective Observational Registry for Obstructive Sleep Apnea in Patients With Acute Myocardial Infarction

N/A

Mosapride citrate 5 mg + DA-9701 30 mg

Functional Dyspepsia

N/A

Clinical Trials (1)

NCT07096921The Effect of Two Prokinetics in Patients With Functional Dyspepsia

N/A

Rivastigmine patch

Alzheimer's Disease

N/A

Clinical Trials (1)

NCT01312363Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

N/A

Experimental

Rotator Cuff Tear

N/A

Clinical Trials (1)

NCT06590714Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.

N/A

The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Steno

Lumbar Spinal Stenosis

N/A

Clinical Trials (1)

NCT06654856The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Stenosis

N/A

Dipeptidyl peptidase-4 inhibitor

Cerebral Infarction

N/A

Clinical Trials (1)

NCT05817097Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

N/A

Tripegfilgrastim

Solid Tumor

Phase 1

Clinical Trials (1)

NCT02963389A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Phase 1

Aricept 5mg Tablet

Healthy

Phase 1

Clinical Trials (1)

NCT04479865Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Phase 1

DA-1229_01 5/1000mg

Healthy

Phase 1

Clinical Trials (1)

NCT05739916Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Phase 1

Udenafil

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT00956306A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function

Phase 1

DA-5216

Healthy

Phase 1

Clinical Trials (1)

NCT05506007A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Phase 1

DA-5215 Tab

Healthy

Phase 1

Clinical Trials (1)

NCT05376085Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"

Phase 1

DA-5210 10/1000mg

Healthy

Phase 1

Clinical Trials (1)

NCT05108571Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State

Phase 1

DA-1229

Diabetes Mellitis Type 2

Phase 1

Clinical Trials (1)

NCT00961025A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects

Phase 1

DA-1229_01

Type2 Diabetes

Phase 1

Clinical Trials (1)

NCT03939143A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State

Phase 1

Evogliptin→Evogliptin+Empagliflozin→Empagliflozin

Type2 Diabetes

Phase 1

Clinical Trials (1)

NCT03766724Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Phase 1

DA-8010 5mg

Healthy

Phase 1

Clinical Trials (1)

NCT05991401Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Phase 1

Vemlidy Tab

Hepatitis B

Phase 1

Clinical Trials (1)

NCT04906109Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

Phase 1

Evogliptin→Evogliptin+Glimepiride→Glimepiride

Type2 Diabetes

Phase 1

Clinical Trials (1)

NCT02954822Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg

Phase 1

Evogliptin, Pioglitazone, Evogliptin+Pioglitazone

Type 2 Diabetes

Phase 1

Clinical Trials (1)

NCT02753803Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Phase 1

DA3880

Symptomatic Anemia

Phase 1

Clinical Trials (1)

NCT02241200A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)

Phase 1

DA-5210 10/500mg

Healthy

Phase 1

Clinical Trials (1)

NCT05098262Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

Phase 1

DA-6886

Irritable Bowel Syndrome

Phase 1

Clinical Trials (1)

NCT01633723Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

Phase 1

DA-4001 H

Androgenic Alopecia

Phase 1

Clinical Trials (1)

NCT02824380Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia

Phase 1

G3041

Healthy Adult Volunteers

Phase 1

Clinical Trials (1)

NCT02058472Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers

Phase 1

Forxiga

Healthy

Phase 1

Clinical Trials (1)

NCT04473417Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Phase 1

SR-exenatide

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01156779Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

Phase 1

DA-6034

Dry Eye Syndrome

Phase 1

Clinical Trials (1)

NCT01162954Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

Phase 1

DA-1229_01

Type2 Diabetes

Phase 1

Clinical Trials (1)

NCT03944200A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State

Phase 1

Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab

Healthy

Phase 1

Clinical Trials (1)

NCT04325009Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"

Phase 1

DA-1229_01

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT02375139A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Phase 1

DA-8010

Overactive Bladder

Phase 1

Clinical Trials (1)

NCT02821312A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects

Phase 1

Imatinib mesylate tablet 400 mg, 1 Tablet

Chronic Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT01751919A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Phase 1

600㎍ of DA-3030 Injection

Diabetic Neuropathy

Phase 1

Clinical Trials (1)

NCT01820715A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

Phase 1

Placebo

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT03061981A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

Phase 1

DA-1241

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT03646721A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Phase 1

DA-1229

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01941199Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects

Phase 1

Aricept 5mg Tablet

Healthy

Phase 1

Clinical Trials (1)

NCT05127746Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Phase 1

DA-3501

Gastric (Stomach) Cancer

Phase 1

Clinical Trials (1)

NCT07481357A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Phase 1

Viread 300mg

Healthy

Phase 1

Clinical Trials (1)

NCT02557594Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers

Phase 1